에 대한 최신 뉴스 IDEXX Laboratories (NASDAQ:IDXX) 주식

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

Chatbot,Conversation,Ai,Artificial,Intelligence,Technology,Online,Customer,Service.digital,Chatbot,

News

Commodities

Markets

AXON

CPNG

IDXX

ISRG

MELI

PCAR

SPOT

케이티 허버티(Katy Huberty)는 모건 스탠리의 글로벌 리서치 책임자로, 인공지능(AI) 도입으로 인해 상당한 이점을 얻을 가능성이 있는 20개의 주식을 주목했다. 무슨 일이 있었나: 허버티는 현재 AI 도입을 위한 &#34;전환점&#34;에 있다고 언급했다. 그녀는 AI를 활용하여 수익을 증대시키는 기업들이 상당한 혜택을 누릴 준비가 되어 있다고 강조했다.

모건 스탠리, 인공지능 채택이 임계치에 도달함에 따라 상위 20개 AI 기반 주식 공개

Healthcare,,Opioid,Epidemic,And,Drug,Abuse,Concept,With,The,Map

Analyst Color

Biotech

Large Cap

Health Care

Analyst Ratings

Trading Ideas

General

ABBV

ELAN

GILD

PRGO

REGN

TEVA

VTRS

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다. 강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다. 

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

IDEXX Laboratories Inc

IDEXX Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NYSE">IDXX</a>) short percent of float has risen 10.37% since its last report. The company recently reported that it has 3.02 million shares sold short, which is 4.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>IDEXX Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743790503_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for IDEXX Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing IDEXX Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, IDEXX Laboratories's peer group average for short interest as a percentage of float is 4.39%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About IDEXX Laboratories?

Legal

U.S. Judge Dismisses Most Of Consumer Lawsuit Against Idexx Laboratories Over Veterinary Service Prices

A substantial insider activity was disclosed on February 12, as Erickson, Executive Vice President at IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), reported the exercise of a large sell of company stock options.
What Happened: Disclosed in a Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000874716/000087471625000008//Archives/edgar/data/874716/000087471625000008/0000874716-25-000008-index.htm">U.S. Securities and Exchange Commission</a>, Erickson, Executive Vice President at IDEXX Laboratories, executed a strategic derivative sale. This involved exercising stock options for 1,544 shares of IDXX, resulting in a transaction value of $597,944.
As of Thursday morning, IDEXX Laboratories shares are down by 0.49%, with a current price of $455.12. This implies that Erickson's 1,544 shares have a value of $597,944.
<h3>Discovering IDEXX Laboratories: A Closer Look</h3>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>IDEXX Laboratories: Delving into Financials</h3>
Decline in Revenue: Over the 3 months period, IDEXX Laboratories faced challenges, resulting in a decline of approximately -2.18% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 59.8%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 2.64, IDEXX Laboratories showcases strong earnings per share.
</li>
</ul>
Debt Management: IDEXX Laboratories's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.54.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 42.86 is lower than the industry average, implying a discounted valuation for IDEXX Laboratories's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 9.77 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 33.7 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Transaction Codes To Focus On</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000874716">Check Out The Full List Of IDEXX Laboratories's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Options Movement At IDEXX Laboratories: Michael G Erickson Exercises Worth $597K

In a new SEC filing on February 11, it was revealed that Fennell, Executive Vice President at IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), executed a significant exercise of company stock options.
What Happened: In an insider options sale disclosed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000874716/000087471625000006//Archives/edgar/data/874716/000087471625000006/0000874716-25-000006-index.htm">U.S. Securities and Exchange Commission</a>, Fennell, Executive Vice President at IDEXX Laboratories, exercised stock options for 11,242 shares of IDXX. The transaction value amounted to $4,280,728.
The Wednesday morning market activity shows IDEXX Laboratories shares down by 0.74%, trading at $460.32. This implies a total value of $4,280,728 for Fennell's 11,242 shares.
<h3>Delving into IDEXX Laboratories's Background</h3>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>A Deep Dive into IDEXX Laboratories's Financials</h3>
Negative Revenue Trend: Examining IDEXX Laboratories's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -2.18% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 59.8%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): IDEXX Laboratories's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 2.64.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.54.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 43.46 is lower than the industry average, implying a discounted valuation for IDEXX Laboratories's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 9.9, IDEXX Laboratories's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 34.17, IDEXX Laboratories presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Exploring Key Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000874716">Check Out The Full List Of IDEXX Laboratories's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Decision: George Fennell Exercises Options At IDEXX Laboratories For $4.28M

A substantial insider sell was reported on February 10, by M. Anne Szostak, Director at IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), based on the recent SEC filing.
What Happened: Szostak's recent move involves selling 3,000 shares of IDEXX Laboratories. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000874716/000087471625000004//Archives/edgar/data/874716/000087471625000004/0000874716-25-000004-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The total value is $1,397,835.
Tracking the Tuesday's morning session, IDEXX Laboratories shares are trading at $463.0, showing a down of 0.41%.
<h3>About IDEXX Laboratories</h3>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>IDEXX Laboratories: A Financial Overview</h3>
Revenue Challenges: IDEXX Laboratories's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -2.18%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 59.8%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): IDEXX Laboratories's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 2.64.
</li>
</ul>
Debt Management: IDEXX Laboratories's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.54.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 43.57 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 9.93 is above industry norms, reflecting an elevated valuation for IDEXX Laboratories's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 34.25, IDEXX Laboratories presents an attractive value opportunity.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000874716">Check Out The Full List Of IDEXX Laboratories's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

M. Anne Szostak Implements A Sell Strategy: Offloads $1.40M In IDEXX Laboratories Stock

Piper Sandler analyst David Westenberg maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Neutral and raises the price target from $435 to $510.

Price Target

Piper Sandler Maintains Neutral on IDEXX Laboratories, Raises Price Target to $510

Barclays analyst Balaji Prasad maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Overweight and raises the price target from $481 to $520.

Barclays Maintains Overweight on IDEXX Laboratories, Raises Price Target to $520

B of A Securities analyst Michael Ryskin maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Neutral and raises the price target from $475 to $535.

B of A Securities Maintains Neutral on IDEXX Laboratories, Raises Price Target to $535

<h3>Gainers</h3>
<ul>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares rose 251.2% to $0.98 during Monday's pre-market session. The market value of their outstanding shares is at $43.5 million. </li>
<li>GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares rose 90.45% to $20.19. The company's market cap stands at $1.0 billion. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) stock moved upwards by 24.68% to $0.45. The company's market cap stands at $53.3 million. </li>
<li>Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) shares increased by 11.8% to $1.8. The company's market cap stands at $79.2 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares rose 10.67% to $6.54. The market value of their outstanding shares is at $8.3 million. </li>
<li>IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) shares increased by 10.41% to $466.0. The market value of their outstanding shares is at $38.1 billion. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) shares decreased by 43.6% to $0.09 during Monday's pre-market session. The company's market cap stands at $3.3 million. </li>
<li>Procaps Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) shares declined by 41.11% to $0.94. The company's market cap stands at $105.7 million. </li>
<li>Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) shares decreased by 18.07% to $3.99. The market value of their outstanding shares is at $55.0 million. </li>
<li>Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) shares declined by 14.6% to $2.75. The market value of their outstanding shares is at $95.0 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) shares fell 12.81% to $0.84. The market value of their outstanding shares is at $498.7 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) stock declined by 10.94% to $2.2. The company's market cap stands at $10.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ANVS

BCDA

ELUT

GHRS

HCWB

IVVD

PROC

QNCX

RDHL

SENS

VIRX

12 Health Care Stocks Moving In Monday's Pre-Market Session

Wall Street bounced back after President Donald Trump and Mexican President Claudia Sheinbaum agreed to a one-month suspension of tariffs following Mexico's pledge to bolster its military presence <a href="https://www.benzinga.com/government/regulations/25/02/43440692/us-mexico-agrees-on-one-month-tariffs-pause-stocks-rebound-peso-rallies">at the northern border.</a>
Earlier on Monday, markets had been rattled by Trump&#8217;s announcement of sweeping tariffs — 25% on all imports from Mexico and Canada and 10% on Chinese goods. The prospect of escalating trade tensions led to sharp early session declines.
The temporary tariff reprieve on Mexico has fueled speculation that Trump may be using tariffs as a negotiation tool rather than a definitive policy, potentially easing concerns they will remain in place if U.S. demands — centered on immigration and drug trafficking — are met.
Trump is set to speak with Canadian Prime Minister Justin Trudeau at 3 p.m. ET.
By midday in New York, the S&amp;P 500 and Nasdaq 100 were down 0.8%, trimming earlier losses, while the Dow nearly erased its decline entirely, reflecting renewed investor confidence in industrial and less tech-sensitive stocks.
Some of the Magnificent Seven stocks remained under pressure. Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) all faced sharp declines, by 6%, 4% and 3.8% respectively, amid concerns over worsening trade relations with China and the risk of retaliatory measures from Beijing.
In fixed income, long-term Treasury yields edged lower, while the U.S. dollar trimmed its early session gains. The Mexican peso rebounded sharply, rising over 1% by 12:30 p.m. ET, recovering from overnight losses of up to 2%.
Commodity markets experienced turbulence. Natural gas prices soared 11% on Monday, surpassing $3 per million British thermal units, while oil climbed 0.8%.
Safe-haven demand remained strong, with gold rallying 0.8% to a record high of over $2,810 per ounce.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) surged back to $99,000 following news of the U.S. pause on Mexico tariffs. 
<h3 class="wp-block-heading">Monday&#8217;s Performance On Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>Chg 1-day %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,433.51</td>
<td>-0.1%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,994.65</td>
<td>-0.8%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,280.79</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,257.74</td>
<td>-1.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:38 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;eased 0.8% to $596.84.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.3% to $443.77.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.9% to $517.15.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) dropped 1.2% to $223.80.</li>
<li>The&nbsp;Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 0.4%; the&nbsp;Technology Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) lagged, down 1.4%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
<ul>
<li>Stocks moving on earnings report include Tyson Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>), up 1.2%, IDEXX Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), up 11.2%. </li>
<li>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>), Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) are among large-cap companies reporting after the close.</li>
<li>Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) tumbled 8% after UBS slashed the stock price target from $67 to $48. </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43439462/us-manufacturing-confidence-tops-forecasts">US Manufacturing Confidence Tops Forecasts, Yet Price Pressures Intensify, &#8216;Could Become A Concern,&#8217; Economist Says</a></li>
</ul>
Photo via Shutterstock.

Equities

Broad U.S. Equity ETFs

Politics

Global

ETFs

$BTC

AAPL

SPDR Dow Jones Industrial Average ETF Trust

NVDA

NXPI

PLTR

TSLA

Stocks Trim Losses On Mexico Tariff Delay, Gold Extends Records, Tesla Sinks 6%: What's Driving Markets Monday?

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Monday.
Shares of IDEXX Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) rose sharply during Monday's session after the company reported better-than-expected quarterly <a href="https://www.benzinga.com/quote/IDXX/earnings">earnings and revenue</a>.
IDEXX Laboratories reported fourth-quarter adjusted EPS of $2.53, up 10% year-over-year, beating the consensus of $2.40.
The pet healthcare company reported sales of $954.3 million, beating the consensus of $934.99 million, up 6% on a reported and organic basis in the fourth quarter, driven by Companion Animal Group (CAG) growth of 6% as reported and organically to $870.47 million.
IDEXX Laboratories shares surged 10.2% to $465.13 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>GH Research PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares jumped 75.4% to $18.59 after the company&#8217;s inhalable depression treatment GH001 met the primary endpoint in its Phase 2b trial, showing symptom reduction.</li>
<li>Triumph Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>) gained 34.2% to $25.16 after the company agreed to go private in a $3 billion deal backed by Warburg Pincus and Berkshire Partners.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) rose 24.3% to $15.62.</li>
<li>zSpace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZSPC#NASDAQ">ZSPC</a>) gained 23% to $21.72 after Roth MKM initiated coverage on the stock with a Buy rating and announced a price target of $20.</li>
<li>Stratasys Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSYS#NASDAQ">SSYS</a>) rose 19.2% to $11.10 after the company reported preliminary fourth-quarter revenue above estimates.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) gained 19% to $25.81.</li>
<li>Qurate Retail, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRTEB#NASDAQ">QRTEB</a>) rose 15.2% to $2.42.</li>
<li>Exodus Movement, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXOD#NYSE">EXOD</a>) gained 10.3% to $55.00.</li>
<li>3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) gained 6.7% to $3.84.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) climbed 6.3% to $116.11.</li>
<li>Dave &amp; Buster&#8217;s Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) rose 6.1% to $28.18. Dave &amp; Buster&#8217;s announced appointment of Scott Ross to Board of Directors.</li>
<li>Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) gained 5.5% to $506.77 following better-than-expected quarterly results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

EXOD

MMYT

PLAY

QRTEB

SAIA

SSYS

ZSPC

IDEXX Laboratories Posts Upbeat Results, Joins Stratasys, Saia And Other Big Stocks Moving Higher On Monday

IDEXX Laboratories&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) reported fourth-quarter adjusted EPS of $2.53, up 10% year-over-year,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of $2.40</a>.
The pet healthcare company reported sales of $954.3 million, beating the consensus of $934.99 million, up 6% on a reported and organic basis in the fourth quarter, driven by Companion Animal Group (CAG) growth of 6% as reported and organically <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43429537/idexx-laboratories-announces-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">to $870.47 million</a>.
CAG Diagnostics recurring revenue gains of 6% reported and 7% organic in the quarter were supported by continued benefits from IDEXX execution drivers, including high-quality placements of CAG Diagnostics capital instruments across regions, high customer retention, new business gains, and net price realization.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">Big Biopharma Trails Behind The Market: JP Morgan&#8217;s 2025 Outlook on Eli Lilly, Merck, and More</a>
Water achieved revenue growth of 8% on a reported basis and 9% on an organic basis to $45.15 million, reflecting benefits from net price improvement and solid gains in the U.S. and Europe.
Livestock, Poultry, and Dairy revenue grew 5% on a reported basis and 7% on an organic basis to $34.56 million, supported by solid gains across the U.S., Europe, and Latin America regions.
Gross margins of 59.8% expanded 140 basis points compared to the prior year on a reported basis and expanded 130 basis points on a comparable basis. Gross margin results reflect benefits from net price improvement, which offset inflationary cost impacts, favorable business mix benefits from strong consumable growth, and higher Water gross margins.
Operating margin was 27.4% in the quarter, 20 basis points higher than the prior year period results on a reported basis and 50 basis points higher on a comparable basis.
Guidance: IDEXX Laboratories provides an initial outlook for 2025 revenue of $4.055 billion—$4.170 billion versus a consensus of $4.14 billion, reflecting growth of 4%—7% reported and 6%—9% organic. This is supported by CAG Diagnostics recurring revenue growth of 3%—6% as reported and <a href="https://www.benzinga.com/calendars/guidance">5%—8% on an organic basis.</a>
Estimates 2025 EPS of $11.74&nbsp;&#8211;&nbsp;$12.24 versus consensus of $11.92, an increase of 10% &#8211; 15% as reported and 8% to 12% on a comparable basis.
Outlook assumes ~$1.5 billion of share repurchases in 2025, subject to market conditions, equivalent to ~4% of current equity market capitalization.
Price Action: IDXX stock is up 11.2% at $469.21 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43432806/tyson-foods-posts-q1-earnings-protein-conscious-customers-drive-demand-ceo-calls-it-best-quarter-in-2-years" target="_blank" rel="noreferrer noopener">Tyson Foods Posts Q1 Earnings: Protein Conscious Customers Drive Demand, CEO Calls It Best Quarter In 2 Years</a></li>
</ul>
Photo via Shutterstock.

Earnings

Guidance

Why Is Pet Health Company IDEXX Laboratories Stock Trading Higher On Monday?

IDEXX Laboratories Exec Says Expect About A 2% Decline In Clinical Visits For 2025

WIIM

IDEXX Laboratories shares are trading higher after the company reported better-than-expected Q4 earnings and revenue.

IDEXX Laboratories Expects 2025 Revenue Of $4.055B-$4.170B Versus A Consensus Of $4.144B

2025 Growth and Financial Performance Outlook
The following table provides the Company's initial estimates for annual key financial metrics in 2025:
Amounts in millions except per share data and percentages
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Growth and Financial Performance Outlook</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">2025</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$4,055</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$4,170</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Reported growth</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">4%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">7%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Organic growth</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">6%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">9%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">CAG Diagnostics Recurring Revenue Growth</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Reported growth</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">3%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">6%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Organic growth</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">5%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">8%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating Margin</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">31.0%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">31.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Reported operating margin expansion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">200</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">250 bps</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Comparable operating margin expansion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">30</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">80 bps</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$11.74</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$12.24</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Reported growth</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">10%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">15%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Comparable growth</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">8%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">12%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other Key Metrics</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net interest expense</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">~ $42</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Share-based compensation tax benefit</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">~ $8</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Share-based compensation tax rate benefit</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">~ 1 %</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective tax rate</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">~ 21.5 %</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Share-based compensation EPS impact</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">~ $0.10</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Reduction in average shares outstanding</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">3%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating Cash Flow</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">100% - 110% of net income</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">85% - 90% of net income</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital Expenditures</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">~ $160</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
The following table outlines estimates of foreign currency exchange rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions reflected in the above financial performance outlook for 2025.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Estimated Foreign Currency Exchange Rate Impacts</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">2025</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue growth rate impact</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">(~ 2%)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">CAG Diagnostics recurring revenue growth rate impact</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">(~ 2%)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating margin growth impact</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">~ 10 bps</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EPS impact</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">(~ $0.21)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EPS growth impact</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">(~ 2%)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Go-forward Foreign Currency Exchange Rate Assumptions</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">In U.S. dollars</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">euro</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">$1.02</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">British pound</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">$1.23</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Canadian dollar</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">$0.68</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Australian dollar</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">$0.61</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Relative to the U.S. dollar</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Japanese yen</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">¥160</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Chinese renminbi</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">¥7.43</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Brazilian real</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">R$6.21</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

IDEXX Laboratories Expects 2025 Adjusted EPS Of $11.71-$12.24 Versus Consensus Of $11.92.

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) reported quarterly earnings of $2.53 per share which beat the analyst consensus estimate of $2.40 by 5.42 percent. This is a 10.48 percent increase over earnings of $2.29 per share from the same period last year. The company reported quarterly sales of $954.29 million which beat the analyst consensus estimate of $934.99 million by 2.06 percent. This is a 5.84 percent increase over sales of $901.60 million the same period last year.

IDEXX Laboratories Q4 2024 Adj EPS $2.53 Beats $2.40 Estimate, Sales $954.29M Beat $934.99M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Tyson Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $13.46 billion. 
• Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) is projected to report quarterly earnings at $2.77 per share on revenue of $780.35 million. 
• Alliance Res Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARLP#NASDAQ">ARLP</a>) is likely to report quarterly earnings at $0.67 per share on revenue of $635.60 million. 
• Johnson Outdoors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JOUT#NASDAQ">JOUT</a>) is estimated to report quarterly loss at $1.30 per share on revenue of $104.73 million. 
• Lavoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVRO#NASDAQ">LVRO</a>) is estimated to report quarterly loss at $0.37 per share on revenue of $373.85 million. 
• NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) is estimated to report quarterly earnings at $0.34 per share on revenue of $49.88 million. 
• Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) is expected to report quarterly loss at $0.63 per share on revenue of $86.95 million. 
• IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is estimated to report quarterly earnings at $2.40 per share on revenue of $936.68 million. 
<h3>Companies Reporting After The Bell</h3>
• BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $524.74 million. 
• New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) is estimated to report quarterly earnings at $1.06 per share on revenue of $468.00 million. 
• Cabot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBT#NYSE">CBT</a>) is likely to report quarterly earnings at $1.77 per share on revenue of $997.10 million. 
• KKR Real Estate Finance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>) is likely to report quarterly loss at $0.07 per share on revenue of $34.78 million. 
• Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is estimated to report quarterly earnings at $2.49 per share on revenue of $813.57 million. 
• Kyndryl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $3.81 billion. 
• Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) is estimated to report quarterly loss at $17.08 per share on revenue of $3.93 billion. 
• Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>) is likely to report quarterly earnings at $1.00 per share on revenue of $754.93 million. 
• Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) is likely to report quarterly earnings at $1.40 per share on revenue of $1.63 billion. 
• J&amp;J Snack Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JJSF#NASDAQ">JJSF</a>) is estimated to report quarterly earnings at $0.59 per share on revenue of $360.85 million. 
• Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $691.84 million. 
• Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) is expected to report quarterly earnings at $0.11 per share on revenue of $775.91 million. 
• MGIC Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTG#NYSE">MTG</a>) is expected to report quarterly earnings at $0.66 per share on revenue of $303.53 million. 
• AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) is estimated to report quarterly earnings at $1.10 per share on revenue of $4.11 billion. 
• Capital Southwest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSWC#NASDAQ">CSWC</a>) is likely to report quarterly earnings at $0.62 per share on revenue of $50.62 million. 
• Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is estimated to report quarterly earnings at $1.18 per share on revenue of $772.98 million. 
• Sun Country Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCY#NASDAQ">SNCY</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $258.04 million. 
• Flexsteel Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXS#NASDAQ">FLXS</a>) is estimated to report quarterly earnings at $0.74 per share on revenue of $104.61 million. 
• RBB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBB#NASDAQ">RBB</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $28.12 million. 
• NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) is likely to report quarterly earnings at $3.13 per share on revenue of $3.10 billion. 
• Kforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFRC#NYSE">KFRC</a>) is projected to report quarterly earnings at $0.59 per share on revenue of $341.43 million. 
• Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) is expected to report quarterly earnings at $0.47 per share on revenue of $160.29 million. 
• NewMarket (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEU#NYSE">NEU</a>) is estimated to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARLP

BRBR

CSWC

FLXS

JJSF

JOUT

KFRC

KREF

LVRO

NSSC

RMBS

SNCY

TWST

Earnings Scheduled For February 3, 2025

Across the recent three months, 4 analysts have shared their insights on IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $491.5, a high estimate of $550.00, and a low estimate of $435.00. Observing a downward trend, the current average is 10.58% lower than the prior average price target of $549.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1738188009_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of IDEXX Laboratories by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$550.00</td>
<td>$559.00</td>
</tr>
<tr>
<td>Daniel Clark</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$500.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$435.00</td>
<td>$520.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$481.00</td>
<td>$570.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to IDEXX Laboratories. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of IDEXX Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for IDEXX Laboratories's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of IDEXX Laboratories's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IDXX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IDEXX Laboratories analyst ratings.</a>
<h2>Delving into IDEXX Laboratories's Background</h2>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>IDEXX Laboratories: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: IDEXX Laboratories's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 6.56%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: IDEXX Laboratories's net margin excels beyond industry benchmarks, reaching 23.87%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): IDEXX Laboratories's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.56% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): IDEXX Laboratories's ROA excels beyond industry benchmarks, reaching 6.88%. This signifies efficient management of assets and strong financial health.
Debt Management: IDEXX Laboratories's debt-to-equity ratio surpasses industry norms, standing at 0.62. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing IDEXX Laboratories: Insights From 4 Financial Analysts

Morgan Stanley analyst Erin Wright maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Overweight and lowers the price target from $559 to $550.

Morgan Stanley Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $550

Press Releases

IDEXX Laboratories to Release 2024 Third Quarter Financial Results

IDEXX Laboratories Announces Third Quarter Results

IDEXX Announces CFO Transition

IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization

SR Inc Announces 2024 SBER Awards: Top Honors Go to Synopsys, Nell Triplett of Juniper Networks, and IDEXX

IDEXX Laboratories to Release 2024 Fourth Quarter and Full Year Financial Results

IDEXX Announces Groundbreaking Cancer Dx Panel with Affordable Early Detection Test for Canine Lymphoma

IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results

IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

IDEXX Laboratories to Release 2025 First Quarter Financial Results

SNPS

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

케이티 허버티(Katy Huberty)는 모건 스탠리의 글로벌 리서치 책임자로, 인공지능(AI) 도입으로 인해 상당한 이점을 얻을 가능성이 있는 20개의 주식을 주목했다.
무슨 일이 있었나: 허버티는 현재 AI 도입을 위한 &#8220;전환점&#8221;에 있다고 언급했다. 그녀는 AI를 활용하여 수익을 증대시키는 기업들이 상당한 혜택을 누릴 준비가 되어 있다고 강조했다.
허버티는 이번 달 초 <a href="https://www.businessinsider.com/ai-adopters-stocks-to-buy-beneficiaries-pricing-power-morgan-stanley-2025-1#home-depot-1">비즈니스 인사이더</a>와의 인터뷰에서 강력한 가격 결정력을 가진 기업, 즉 높은 수요로 인해 가격을 유지하거나 인상할 수 있는 기업들이 가장 큰 수익성 향상을 경험할 것이라고 지적했다.
그녀는 &#8220;가격 결정력은 기업들이 이러한 투자로 인한 생산성 향상을 고객에게 전가하지 않고 유지할 수 있게 해 줄 것&#8221;이라고 설명했다.
또한, 허버티는 그녀의 팀이 고객 노트에서 작성한 주식 목록을 언급했다. 이 주식들은 모두 AI를 도입하고 높은 가격 결정력을 가진 기업들로, 시가총액이 200억 달러 이상이다. 목록에는 홈디포(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>), 써모 피셔 사이언티픽(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), 인튜이티브 서지컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), 디어 앤 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>), 스포티파이 테크놀로지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>), 메르카도리브레(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), 메리어트 인터내셔널(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>), 힐튼 월드와이드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>), 파카(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>), 슐럼버거 NV(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>), 존슨 컨트롤스 인터내셔널 PLC(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>), 엑슨 엔터프라이즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>), 쿠팡(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>), 베이커 휴즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), 익스피리언 PLC, 델타 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), 아이덱스 래버러토리스(NASDAQ:<a class="ticker" style="font-size: revert;" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), 유나이티드 에어라인 홀딩스(NASDAQ:<a class="ticker" style="font-size: revert;" href="https://www.benzinga.com/stock/UA#NASDAQ">UA</a>) 및 할리버튼(NYSE:<a class="ticker" style="font-size: revert;" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) 등이 포함되어 있다.
왜 중요한가요: AI 도입은 최근 몇 년간 뜨거운 주제가 되었으며, 많은 산업에서 비즈니스 운영을 혁신하고 수익성을 높일 수 있는 잠재력을 인식하고 있다.
허버티가 이러한 20개 주식을 지적한 것은 비즈니스 환경에서 AI의 중요성이 커지고 있음을 강조한다. AI 기술을 성공적으로 활용하는 기업들은 경쟁 우위를 얻을 수 있으며, 특히 강력한 가격 결정력을 가진 기업들이 그렇다.
이러한 발전은 투자 전략의 변화를 시사할 수 있으며, 투자자들이 강력한 AI 도입을 가진 기업들을 유망한 투자 기회로 보게 될 가능성이 있다.
다음 읽을거리:
<a href="https://www.benzinga.com/markets/25/01/43217038/aoc-says-democrats-in-congress-are-doing-insider-trading-people-think-that-everyday-people-are-stupid">AOC, &#8220;의회 민주당원들이 내부자 거래를 하고 있다&#8221;: &#8216;사람들은 일반 사람들이 바보라고 생각한다&#8217;</a>
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다.
강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다.
2024년 바이오제약 주식은 9.6% 상승하여 S&amp;P 500의 28.5% 상승률에 미치지 못했다. 그러나 JP모건 애널리스트들은 몇몇 주요 기업에 대해 긍정적인 전망을 유지하고 있다.
JP모건에서 가장 많이 추천하는 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 당뇨병 및 비만 치료제인 <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">마운자로(Mounjaro)와 젭바운드(Zepbound)</a>에서 지속적인 성장을 보일 것으로 예상된다. 또한 JP모건은 일라이 릴리의 강력한 파이프라인을 강조하면서 2030년대까지 두 자릿수 매출과 수익 성장을 예측했다.
브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 최고 매출 100억 달러를 달성할 수 있는 조현병 치료제인 코벤피(Cobenfy)의 강력한 잠재력으로 JP모건의 &#8216;포커스 리스트&#8217;에 추가되었다.
마찬가지로 머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)와 리제네론 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an">주요 제품에 영향을 미치는</a> <a href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare">경쟁 압력</a> 및 지역 역학과 관련된 2024년의 어려움에 이어 2025년에는 회복될 것이르오 예상된다.
길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)는 <a href="https://www.benzinga.com/quote/GILD">HIV 예방을 위한</a> 레나카파비르(lenacapavir)의 2025년 중반 출시가 예상됨에 따라 성장할 것으로 예상된다.
또한 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)는 단기적인 <a href="https://www.benzinga.com/quote/ABBV">파이프라인 개발</a>이 적음에도 불구하고 스카이리지(Skyrizi)와 린보크(Rinvoq) 판매 호조에 힘입어 밸류에이션이 매력적이라고 보았다.
한편, 동물 건강 관련 주식도 2025년에 반등할 것으로 예상한다. JP 모건은 조에티스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>)를 이 분야에서 가장 강력한 선택지로 보고 있으며, 고배당 매출 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" target="_blank" rel="noreferrer noopener">성장과 마진 확장</a>의 잠재력을 언급했다. 아이덱스 래버러토리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>)는 또 다른 다른 확실한 선택이며, 성과는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" target="_blank" rel="noreferrer noopener">수의사 방문 수 회복</a>에 달려 있다. 한편 엘랑코 애니멀 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" target="_blank" rel="noreferrer noopener">신제품 출시</a>와 관련된 불확실성에 직면해 있다.
그리고 특수 의약품 부문은 2024년에 가격 안정성과 공급 역학 개선의 혜택을 받아 조기에 안정화 조짐을 보였다. 페리고(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>)와 비아트리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)는 유망한 기회로 강조되었으며 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)는 올해 강력한 임상 시험 <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" target="_blank" rel="noreferrer noopener">결과를 발표했지만</a> 성장 문제에 직면할 수 있다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%80%80%ED%85%80-%EC%BB%B4%ED%93%A8%ED%8C%85-%EB%B8%94%EB%9E%99%EB%B2%A0%EB%A6%AC-%EB%A3%A8%EC%8B%9C%EB%93%9C-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EB%8C%80-%EC%83%81%EC%8A%B9%ED%95%9C/">퀀텀 컴퓨팅, 블랙베리, 루시드 등 지난주 최대 상승한 중형주 (12월 16일~20일)</a>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

IDEXX Laboratories

뉴스

에 대한 최신 뉴스 IDEXX Laboratories (NASDAQ:IDXX) 주식

월요일, 1월 27, 2025

월요일, 12월 23, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌